anastrozole ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
aromatase inhibitors, imidazole-triazole derivatives 210 120511-73-1

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • anastrozole
  • anastrazole
  • anastrol
  • arimidex
A nitrile and triazole derivative that acts as a selective nonsteroidal aromatase inhibitor. It is used in the treatment of ESTROGEN NUCLEAR RECEPTOR-positive breast cancer in postmenopausal women.
  • Molecular weight: 293.37
  • Formula: C17H19N5
  • CLOGP: 1.75
  • LIPINSKI: 0
  • HAC: 5
  • HDO: 0
  • TPSA: 78.29
  • ALOGS: -3.65
  • ROTB: 4

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
1 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.50 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 10 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.06 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 80 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

DateAgencyCompanyOrphan
Dec. 27, 1995 FDA ASTRAZENECA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Metastases to bone 950.77 11.36 410 43113 17585 50544016
Malignant neoplasm progression 700.60 11.36 531 42992 67593 50494008
Metastases to liver 509.43 11.36 277 43246 19827 50541774
Metastases to lung 404.56 11.36 195 43328 10825 50550776
Osteonecrosis 341.78 11.36 223 43300 22294 50539307
Hot flush 292.24 11.36 267 43256 43902 50517699
Breast cancer recurrent 255.57 11.36 103 43420 3705 50557896
Breast cancer metastatic 249.18 11.36 138 43385 10226 50551375
Bone pain 230.98 11.36 242 43281 46987 50514614
Drug ineffective 218.64 11.36 231 43292 819102 49742499
Disease progression 208.06 11.36 328 43195 95538 50466063
Metastases to lymph nodes 206.70 11.36 107 43416 6917 50554684
Breast cancer 203.02 11.36 216 43307 42674 50518927
Neoplasm progression 180.68 11.36 170 43353 28987 50532614
Osteonecrosis of jaw 161.37 11.36 168 43355 32358 50529243
Neutropenia 157.15 11.36 374 43149 147591 50414010
Tumour marker increased 153.26 11.36 72 43451 3768 50557833
Tooth extraction 135.50 11.36 89 43434 8986 50552615
Ejection fraction decreased 128.38 11.36 115 43408 18405 50543196
Maternal exposure during pregnancy 123.15 11.36 3 43520 159775 50401826
Arthralgia 121.33 11.36 716 42807 437986 50123615
Pseudocirrhosis 115.62 11.36 36 43487 594 50561007
Metastases to spine 106.60 11.36 51 43472 2780 50558821
Metastasis 101.72 11.36 57 43466 4318 50557283
Systemic lupus erythematosus 91.36 11.36 8 43515 140614 50420987
Bone lesion 90.34 11.36 56 43467 5114 50556487
Infusion related reaction 88.29 11.36 19 43504 169538 50392063
Carbohydrate antigen 15-3 increased 87.79 11.36 34 43489 1098 50560503
Trigger finger 87.11 11.36 49 43474 3739 50557862
White blood cell count decreased 86.21 11.36 258 43265 116464 50445137
Therapeutic product effect decreased 85.06 11.36 9 43514 136041 50425560
Osteopenia 82.77 11.36 87 43436 16931 50544670
Completed suicide 81.75 11.36 9 43514 131880 50429721
Bone disorder 80.93 11.36 90 43433 18662 50542939
Vitreoretinal traction syndrome 78.77 11.36 13 43510 0 50561601
Synovitis 77.93 11.36 8 43515 123857 50437744
Osteolysis 75.36 11.36 39 43484 2518 50559083
Treatment failure 74.61 11.36 14 43509 137623 50423978
Rheumatoid arthritis 74.10 11.36 41 43482 202509 50359092
Neuropathy peripheral 69.66 11.36 212 43311 96545 50465056
Acute myeloid leukaemia 64.45 11.36 72 43451 15002 50546599
Tonsillar disorder 62.66 11.36 26 43497 1008 50560593
Organising pneumonia 62.12 11.36 43 43480 4731 50556870
Joint swelling 61.78 11.36 72 43451 245214 50316387
Breast cancer female 60.64 11.36 49 43474 6813 50554788
Myalgia 56.38 11.36 234 43289 124085 50437516
Nasal disorder 56.19 11.36 31 43492 2277 50559324
Retinal toxicity 55.96 11.36 25 43498 1163 50560438
Malignant pleural effusion 55.92 11.36 31 43492 2299 50559302
Pain in jaw 55.39 11.36 110 43413 38318 50523283
Cystoid macular oedema 55.11 11.36 26 43497 1373 50560228
Ascites 54.54 11.36 105 43418 35756 50525845
Sequestrectomy 54.50 11.36 22 43501 794 50560807
Metastases to pleura 53.70 11.36 25 43498 1281 50560320
Debridement 52.96 11.36 24 43499 1155 50560446
Lacrimation increased 52.75 11.36 69 43454 16923 50544678
Glossodynia 52.45 11.36 17 43506 115552 50446049
Lymphoedema 52.33 11.36 51 43472 9071 50552530
Drug hypersensitivity 50.92 11.36 86 43437 250924 50310677
Metastases to central nervous system 50.15 11.36 55 43468 11227 50550374
Toxicity to various agents 47.68 11.36 68 43455 212431 50349170
Hypersensitivity 47.15 11.36 70 43453 215091 50346510
Metastases to the mediastinum 46.97 11.36 17 43506 453 50561148
Osteomyelitis 46.36 11.36 75 43448 22278 50539323
Invasive ductal breast carcinoma 45.50 11.36 39 43484 5882 50555719
Pericarditis 44.84 11.36 7 43516 78682 50482919
PIK3CA-activated mutation 44.51 11.36 19 43504 791 50560810
Fatigue 44.28 11.36 853 42670 706748 49854853
Peritoneal disorder 44.01 11.36 16 43507 432 50561169
Bone sequestrum 43.46 11.36 22 43501 1356 50560245
Metastases to pelvis 43.32 11.36 15 43508 350 50561251
Endometrial hyperplasia 42.75 11.36 18 43505 724 50560877
Abdominal discomfort 41.12 11.36 86 43437 231555 50330046
Wound 40.75 11.36 20 43503 105774 50455827
Interstitial lung disease 39.64 11.36 118 43405 53058 50508543
Vulvovaginal dryness 38.70 11.36 24 43499 2193 50559408
Oestradiol increased 38.69 11.36 10 43513 80 50561521
Hair growth abnormal 37.94 11.36 25 43498 2536 50559065
Hypotension 37.28 11.36 93 43430 235376 50326225
Pleural neoplasm 36.91 11.36 12 43511 229 50561372
Intentional overdose 36.91 11.36 5 43518 62499 50499102
Pathological fracture 36.86 11.36 39 43484 7643 50553958
Nail disorder 35.84 11.36 43 43480 9665 50551936
Pleural effusion 35.10 11.36 151 43372 81303 50480298
Off label use 34.39 11.36 253 43270 474173 50087428
Hypertensive angiopathy 33.88 11.36 9 43514 81 50561520
Metastatic neoplasm 33.58 11.36 27 43496 3727 50557874
Oestrogen receptor assay positive 33.27 11.36 13 43510 430 50561171
Second primary malignancy 33.00 11.36 35 43488 6879 50554722
Leukopenia 32.89 11.36 130 43393 67398 50494203
Carpal tunnel syndrome 32.76 11.36 55 43468 16838 50544763
Metastases to chest wall 32.31 11.36 13 43510 465 50561136
Sialoadenitis 31.89 11.36 18 43505 1382 50560219
Tendonitis 31.88 11.36 54 43469 16651 50544950
Sinusitis 31.38 11.36 62 43461 170496 50391105
Injection site erythema 30.67 11.36 13 43510 74923 50486678
Uterine polyp 30.51 11.36 19 43504 1749 50559852
Pancreatic neoplasm 30.47 11.36 14 43509 696 50560905
Intentional product use issue 30.44 11.36 14 43509 76904 50484697
Thrombocytopenia 30.43 11.36 201 43322 127472 50434129
Product substitution issue 30.29 11.36 48 43475 14009 50547592
Arthropathy 30.27 11.36 56 43467 157850 50403751
Dental care 29.74 11.36 15 43508 917 50560684
Palmar-plantar erythrodysaesthesia syndrome 29.52 11.36 58 43465 20040 50541561
Metastases to soft tissue 28.76 11.36 9 43514 151 50561450
Injection site pain 28.55 11.36 32 43491 110992 50450609
Acute phase reaction 28.34 11.36 10 43513 247 50561354
Swelling 28.28 11.36 84 43439 200788 50360813
Joint stiffness 28.27 11.36 73 43450 30235 50531366
Gingivitis 28.11 11.36 33 43490 7251 50554350
Musculoskeletal chest pain 27.94 11.36 54 43469 18432 50543169
Vitreous detachment 27.77 11.36 18 43505 1776 50559825
Chronic inflammatory demyelinating polyradiculoneuropathy 27.76 11.36 11 43512 378 50561223
Dry skin 27.72 11.36 91 43432 43100 50518501
Injection site reaction 27.28 11.36 5 43518 50027 50511574
Tooth loss 27.28 11.36 30 43493 6140 50555461
Metastases to skin 26.78 11.36 16 43507 1367 50560234
Progesterone receptor assay positive 26.77 11.36 10 43513 292 50561309
Metastases to peritoneum 26.67 11.36 21 43502 2812 50558789
Human epidermal growth factor receptor negative 26.36 11.36 5 43518 6 50561595
Irritable bowel syndrome 26.27 11.36 6 43517 51435 50510166
Fibrous histiocytoma 26.00 11.36 11 43512 448 50561153
Metastases to thorax 25.79 11.36 9 43514 215 50561386
Breast pain 25.56 11.36 32 43491 7512 50554089
Superinfection 25.54 11.36 18 43505 2038 50559563
Bone density decreased 25.51 11.36 39 43484 11036 50550565
Periodontal disease 25.48 11.36 16 43507 1494 50560107
Pneumonia 25.40 11.36 206 43317 378195 50183406
Hormone receptor positive breast cancer 25.39 11.36 11 43512 475 50561126
Portal hypertension 25.37 11.36 22 43501 3370 50558231
Dysgeusia 24.98 11.36 82 43441 38834 50522767
Radiation skin injury 24.96 11.36 13 43510 850 50560751
Discomfort 24.96 11.36 34 43489 108346 50453255
Exposed bone in jaw 24.75 11.36 20 43503 2780 50558821
Condition aggravated 24.68 11.36 152 43371 296906 50264695
Metastases to retroperitoneum 24.59 11.36 8 43515 153 50561448
Product use issue 24.45 11.36 58 43465 149417 50412184
Injection site pruritus 24.42 11.36 3 43520 40408 50521193
Polyneuropathy 24.20 11.36 40 43483 12091 50549510
Metastases to abdominal wall 24.16 11.36 7 43516 89 50561512
Recall phenomenon 23.97 11.36 11 43512 545 50561056
Therapeutic product effect incomplete 23.94 11.36 26 43497 91489 50470112
Drug intolerance 23.92 11.36 102 43421 219002 50342599
Excessive eye blinking 23.84 11.36 13 43510 933 50560668
Recurrent cancer 23.27 11.36 16 43507 1741 50559860
Tooth disorder 23.26 11.36 59 43464 24169 50537432
Fracture 22.84 11.36 47 43476 16786 50544815
Retinal detachment 22.78 11.36 25 43498 5104 50556497
Cutaneous vasculitis 22.46 11.36 23 43500 4339 50557262
Overdose 22.25 11.36 32 43491 99695 50461906
Hepatic lesion 22.23 11.36 22 43501 3986 50557615
Antisynthetase syndrome 22.20 11.36 6 43517 58 50561543
Tumour marker decreased 22.20 11.36 6 43517 58 50561543
Haemorrhoids 22.18 11.36 50 43473 19003 50542598
Muscle injury 21.83 11.36 3 43520 37108 50524493
Loss of personal independence in daily activities 21.76 11.36 17 43506 70033 50491568
Bone debridement 21.47 11.36 8 43515 232 50561369
Autoimmune pancreatitis 21.37 11.36 8 43515 235 50561366
Folliculitis 21.22 11.36 4 43519 39221 50522380
Psoriatic arthropathy 21.18 11.36 7 43516 47025 50514576
Osteosclerosis 21.05 11.36 20 43503 3447 50558154
Ischaemic stroke 21.01 11.36 44 43479 15904 50545697
Vertebral column mass 21.00 11.36 7 43516 145 50561456
Neoplasm malignant 20.97 11.36 56 43467 23659 50537942
Vascular purpura 20.83 11.36 13 43510 1201 50560400
Osteoporosis 20.73 11.36 85 43438 44794 50516807
Cardiomyopathy 20.54 11.36 43 43480 15543 50546058
Jaw operation 20.44 11.36 11 43512 769 50560832
Henoch-Schonlein purpura 20.40 11.36 12 43511 996 50560605
Anaphylactic reaction 19.65 11.36 11 43512 54044 50507557
Blood copper increased 19.53 11.36 4 43519 9 50561592
Cholestasis 19.53 11.36 57 43466 25344 50536257
Papilloedema 19.14 11.36 19 43504 3454 50558147
Transient acantholytic dermatosis 19.13 11.36 5 43518 42 50561559
Neoplasm recurrence 19.01 11.36 16 43507 2353 50559248
Mouth swelling 19 11.36 20 43503 3896 50557705
Pain 18.84 11.36 368 43155 578535 49983066
Gastrointestinal disorder 18.54 11.36 33 43490 94423 50467178
Carcinoembryonic antigen increased 18.53 11.36 13 43510 1461 50560140
Jaw disorder 18.42 11.36 22 43501 4921 50556680
Carbohydrate antigen 27.29 increased 18.35 11.36 5 43518 50 50561551
Hepatic enzyme increased 18.22 11.36 59 43464 137321 50424280
Suicide attempt 18.13 11.36 11 43512 51721 50509880
Blood alkaline phosphatase increased 18.07 11.36 72 43451 37454 50524147
Autoimmune hepatitis 18.06 11.36 27 43496 7492 50554109
Borrelia infection 17.87 11.36 6 43517 127 50561474
Gene mutation 17.85 11.36 12 43511 1259 50560342
Peripheral swelling 17.81 11.36 104 43419 205832 50355769
Tongue neoplasm malignant stage unspecified 17.80 11.36 10 43513 761 50560840
Peripheral sensory neuropathy 17.77 11.36 25 43498 6566 50555035
Gingival swelling 17.74 11.36 19 43504 3776 50557825
Osteitis 17.59 11.36 17 43506 2993 50558608
Bone marrow failure 17.54 11.36 58 43465 27566 50534035
Nasopharyngitis 17.45 11.36 96 43427 192831 50368770
Injection site bruising 17.41 11.36 5 43518 36763 50524838
Nail avulsion 17.41 11.36 6 43517 138 50561463
Vaginal discharge 17.39 11.36 22 43501 5218 50556383
Jaundice 17.24 11.36 56 43467 26373 50535228
Nail infection 17.19 11.36 14 43509 1967 50559634
Hair colour changes 17.09 11.36 16 43507 2708 50558893
Uterine leiomyoma 17.08 11.36 27 43496 7864 50553737
Paraesthesia 16.98 11.36 168 43355 120075 50441526
Endometrial hypertrophy 16.88 11.36 7 43516 271 50561330
Cardio-respiratory arrest 16.84 11.36 13 43510 53879 50507722
Multiple sclerosis relapse 16.72 11.36 8 43515 42956 50518645
Breast mass 16.71 11.36 24 43499 6425 50555176
Vitreous adhesions 16.62 11.36 4 43519 23 50561578
Hiccups 16.61 11.36 13 43510 1726 50559875
Hair texture abnormal 16.55 11.36 18 43505 3638 50557963
Acute promyelocytic leukaemia 16.53 11.36 10 43513 874 50560727
Urticaria 16.25 11.36 57 43466 129504 50432097
Invasive lobular breast carcinoma 16.25 11.36 9 43514 666 50560935
Pustule 16.25 11.36 11 43512 1167 50560434
HER2 positive breast cancer 16.12 11.36 7 43516 304 50561297
Neuroectodermal neoplasm 16.10 11.36 3 43520 3 50561598
Heart rate increased 16.07 11.36 26 43497 77224 50484377
Gamma-glutamyltransferase increased 16.04 11.36 59 43464 29564 50532037
Atrial enlargement 16.01 11.36 7 43516 309 50561292
Oroantral fistula 15.81 11.36 6 43517 183 50561418
Blister 15.74 11.36 31 43492 85387 50476214
Actinomycosis 15.68 11.36 10 43513 959 50560642
Purulent discharge 15.68 11.36 19 43504 4313 50557288
Meningioma 15.65 11.36 17 43506 3432 50558169
Asthenia 15.41 11.36 371 43152 318671 50242930
Oral surgery 15.30 11.36 10 43513 1001 50560600
Visual acuity reduced 15.29 11.36 45 43478 20094 50541507
Septic shock 15.22 11.36 16 43507 57159 50504442
Cardiotoxicity 15.15 11.36 24 43499 7003 50554598
Pyrexia 15.13 11.36 233 43290 379970 50181631
Paratracheal lymphadenopathy 15.06 11.36 4 43519 36 50561565
Radiation pneumonitis 15.01 11.36 11 43512 1324 50560277
Blood pressure fluctuation 15 11.36 6 43517 35817 50525784
Oestradiol abnormal 14.96 11.36 4 43519 37 50561564
Tremor 14.79 11.36 50 43473 114853 50446748
Mucosal inflammation 14.73 11.36 71 43452 40071 50521530
Psoriasis 14.56 11.36 23 43500 68977 50492624
Dysaesthesia 14.54 11.36 17 43506 3718 50557883
Hyperkalaemia 14.52 11.36 12 43511 48077 50513524
Acquired gene mutation 14.51 11.36 9 43514 822 50560779
Flushing 14.46 11.36 22 43501 66993 50494608
Disease recurrence 14.43 11.36 44 43479 20037 50541564
Hypoaesthesia teeth 14.34 11.36 4 43519 44 50561557
Benign lymph node neoplasm 14.29 11.36 3 43520 8 50561593
Wrong technique in product usage process 14.26 11.36 16 43507 55494 50506107
Postoperative wound complication 14.15 11.36 9 43514 859 50560742
Metastases to heart 14.10 11.36 4 43519 47 50561554
Toothache 14.04 11.36 39 43484 16855 50544746
Abdominal wall cyst 14.03 11.36 3 43520 9 50561592
Hypercholesterolaemia 13.94 11.36 31 43492 11672 50549929
Dental caries 13.92 11.36 28 43495 9839 50551762
Left ventricular dysfunction 13.86 11.36 29 43494 10477 50551124
Atypical femur fracture 13.78 11.36 19 43504 4897 50556704
Romberg test positive 13.75 11.36 5 43518 135 50561466
Erysipelas 13.46 11.36 22 43501 6586 50555015
Metastases to adrenals 13.36 11.36 8 43515 686 50560915
Bacteriuria 13.29 11.36 8 43515 693 50560908
Cardiac arrest 13.24 11.36 33 43490 83618 50477983
Chronic hepatic failure 13.21 11.36 7 43516 474 50561127
Hyperthyroidism 13.12 11.36 31 43492 12144 50549457
Tachycardia 13.12 11.36 43 43480 99720 50461881
Renal vein thrombosis 13.08 11.36 6 43517 297 50561304
Alopecia 13.07 11.36 289 43234 244758 50316843
Decreased appetite 13.05 11.36 244 43279 200679 50360922
Sedation 13.03 11.36 5 43518 30605 50530996
Varicophlebitis 12.99 11.36 3 43520 14 50561587
Breast haemorrhage 12.87 11.36 5 43518 163 50561438
Squamous cell breast carcinoma 12.82 11.36 3 43520 15 50561586
Nausea 12.70 11.36 734 42789 704664 49856937
Uveitis 12.63 11.36 26 43497 9284 50552317
Stomatitis 12.60 11.36 138 43385 101206 50460395
Red blood cell count decreased 12.53 11.36 60 43463 33775 50527826
Incorrect dose administered 12.39 11.36 14 43509 48400 50513201
Intraductal proliferative breast lesion 12.33 11.36 13 43510 2537 50559064
Metastases to ovary 12.26 11.36 6 43517 344 50561257
Dyshidrotic eczema 12.23 11.36 7 43516 552 50561049
Acquired porokeratosis 12.22 11.36 3 43520 19 50561582
Rash 12.18 11.36 285 43238 437186 50124415
Breast cancer in situ 12.18 11.36 10 43513 1421 50560180
Gingival ulceration 12.12 11.36 8 43515 814 50560787
Cardiac failure 12.10 11.36 109 43414 75931 50485670
Knee arthroplasty 12.04 11.36 8 43515 35838 50525763
Agitation 12.03 11.36 17 43506 53367 50508234
Oral pain 12.02 11.36 48 43475 24985 50536616
Anaemia 12.00 11.36 293 43230 252163 50309438
Periodontitis 12 11.36 14 43509 3055 50558546
Subacute cutaneous lupus erythematosus 11.99 11.36 12 43511 2203 50559398
Chronic hepatitis 11.96 11.36 8 43515 832 50560769
Diabetic hyperosmolar coma 11.96 11.36 6 43517 363 50561238
Lower limb fracture 11.95 11.36 33 43490 14213 50547388
Mastectomy 11.95 11.36 10 43513 1459 50560142
Pelvic mass 11.94 11.36 9 43514 1130 50560471
Blood oestrogen increased 11.73 11.36 4 43519 89 50561512
Therapeutic response decreased 11.72 11.36 14 43509 47217 50514384
Retinopathy 11.67 11.36 13 43510 2699 50558902
Bronchitis 11.65 11.36 48 43475 104111 50457490
Mood swings 11.50 11.36 35 43488 15919 50545682
Menopause 11.50 11.36 12 43511 2315 50559286
Influenza 11.49 11.36 39 43484 89499 50472102
Unresponsive to stimuli 11.46 11.36 6 43517 30603 50530998
Visual field defect 11.45 11.36 19 43504 5760 50555841
Glomerulonephritis 11.44 11.36 10 43513 1549 50560052

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Growth retardation 89.90 25.71 20 1481 1616 29571410
Mesenteric vein thrombosis 55.90 25.71 11 1490 487 29572539
Secondary hypogonadism 48.91 25.71 9 1492 277 29572749
Metastases to bone 43.46 25.71 17 1484 9881 29563145
Haematocrit increased 42.40 25.71 11 1490 1697 29571329
Spondylolisthesis 40.93 25.71 9 1492 687 29572339
Off label use 40.90 25.71 62 1439 300738 29272288
Glucose tolerance decreased 37.88 25.71 6 1495 73 29572953
Blood testosterone increased 37.79 25.71 9 1492 979 29572047
Autoimmune thyroiditis 37.36 25.71 9 1492 1027 29571999
Breast cancer recurrent 36.61 25.71 5 1496 19 29573007
Product use issue 34.26 25.71 25 1476 51419 29521607
Oestradiol increased 31.55 25.71 5 1496 61 29572965
Performance enhancing product use 31.12 25.71 5 1496 67 29572959
Portal vein thrombosis 31.07 25.71 10 1491 3299 29569727
Osteonecrosis of jaw 29.18 25.71 15 1486 16495 29556531
Insulin-like growth factor increased 26.82 25.71 7 1494 1104 29571922
Androgenetic alopecia 26.67 25.71 3 1498 0 29573026

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Metastases to bone 661.91 11.82 288 34749 20147 64443548
Metastases to liver 341.06 11.82 193 34844 23748 64439947
Malignant neoplasm progression 332.74 11.82 356 34681 112515 64351180
Metastases to lung 322.21 11.82 160 34877 15104 64448591
Hot flush 274.42 11.82 216 34821 46019 64417676
Breast cancer recurrent 253.07 11.82 82 34955 2501 64461194
Breast cancer metastatic 228.59 11.82 100 34937 7069 64456626
Breast cancer 212.43 11.82 154 34883 28994 64434701
Osteonecrosis 209.96 11.82 151 34886 28078 64435617
Bone pain 199.46 11.82 182 34855 47390 64416305
Arthralgia 194.99 11.82 604 34433 441656 64022039
Metastases to lymph nodes 165.28 11.82 85 34952 8632 64455063
Neoplasm progression 139.94 11.82 140 34897 40824 64422871
Pseudocirrhosis 131.13 11.82 36 35001 609 64463086
Osteonecrosis of jaw 121.35 11.82 128 34909 39697 64423998
Tumour marker increased 119.40 11.82 51 34986 3399 64460296
Disease progression 114.90 11.82 244 34793 141436 64322259
Drug ineffective 108.19 11.82 182 34855 840065 63623630
Tooth extraction 106.78 11.82 66 34971 9535 64454160
Carbohydrate antigen 15-3 increased 103.51 11.82 33 35004 954 64462741
Osteopenia 101.73 11.82 77 34960 15463 64448232
Ejection fraction decreased 101.52 11.82 100 34937 28607 64435088
Metastases to spine 97.59 11.82 45 34992 3598 64460097
Completed suicide 87.08 11.82 10 35027 224404 64239291
Fatigue 86.38 11.82 697 34340 748033 63715662
Vitreoretinal traction syndrome 84.74 11.82 13 35024 0 64463695
Bone lesion 80.17 11.82 44 34993 5093 64458602
Alopecia 78.92 11.82 233 34804 165457 64298238
Trigger finger 77.27 11.82 38 34999 3507 64460188
Tonsillar disorder 75.10 11.82 26 35011 975 64462720
Neutropenia 68.07 11.82 284 34753 239340 64224355
Toxicity to various agents 66.27 11.82 60 34977 363453 64100242
White blood cell count decreased 65.89 11.82 212 34825 157625 64306070
Retinal toxicity 64.33 11.82 25 35012 1305 64462390
Osteolysis 60.96 11.82 30 35007 2773 64460922
Cystoid macular oedema 60.65 11.82 26 35011 1748 64461947
Invasive ductal breast carcinoma 54.39 11.82 34 35003 5008 64458687
Nasal disorder 54.31 11.82 28 35009 2856 64460839
Malignant pleural effusion 53.56 11.82 28 35009 2939 64460756
Bone disorder 53.06 11.82 55 34982 16704 64446991
Lacrimation increased 52.40 11.82 57 34980 18289 64445406
Metastasis 50.61 11.82 34 35003 5661 64458034
Lymphoedema 49.70 11.82 42 34995 9863 64453832
Endometrial hyperplasia 49.37 11.82 16 35021 488 64463207
Neuropathy peripheral 48.24 11.82 157 34880 117368 64346327
Metastases to pleura 48.13 11.82 20 35017 1244 64462451
Hypotension 47.43 11.82 84 34953 380890 64082805
Peritoneal disorder 45.40 11.82 16 35021 633 64463062
Vulvovaginal dryness 43.50 11.82 20 35017 1588 64462107
Myalgia 42.66 11.82 185 34852 158432 64305263
Infusion related reaction 42.58 11.82 18 35019 164449 64299246
Pleural neoplasm 42.45 11.82 12 35025 227 64463468
Nail disorder 42.11 11.82 36 35001 8588 64455107
Pneumonia 41.59 11.82 160 34877 559416 63904279
Acute myeloid leukaemia 41.27 11.82 62 34975 27401 64436294
Pain in jaw 41.16 11.82 77 34960 40678 64423017
Metastases to central nervous system 41.09 11.82 44 34993 13868 64449827
Maternal exposure during pregnancy 40.56 11.82 3 35034 95881 64367814
Therapeutic product effect decreased 40.36 11.82 7 35030 115344 64348351
Oestrogen receptor assay positive 40.32 11.82 12 35025 274 64463421
Sialoadenitis 40.11 11.82 19 35018 1614 64462081
Carpal tunnel syndrome 39.77 11.82 46 34991 15782 64447913
Uterine polyp 37.52 11.82 17 35020 1305 64462390
Oestradiol increased 37.23 11.82 9 35028 89 64463606
Osteoporosis 37.01 11.82 75 34962 42005 64421690
Drug abuse 36.72 11.82 13 35024 132361 64331334
Joint stiffness 36.56 11.82 62 34975 30342 64433353
Hypertensive angiopathy 36.44 11.82 9 35028 98 64463597
Intentional overdose 34.88 11.82 4 35033 89940 64373755
Synovitis 34.70 11.82 6 35031 99084 64364611
Debridement 34.16 11.82 17 35020 1609 64462086
Vitreous detachment 34.11 11.82 18 35019 1926 64461769
Hair growth abnormal 33.57 11.82 19 35018 2333 64461362
Overdose 33.22 11.82 23 35014 159543 64304152
Metastases to pelvis 32.88 11.82 12 35025 526 64463169
Breast cancer female 32.76 11.82 25 35012 5078 64458617
Metastases to chest wall 32.63 11.82 11 35026 380 64463315
Acute phase reaction 31.53 11.82 10 35027 284 64463411
Treatment failure 31.51 11.82 12 35025 116804 64346891
Vaginal discharge 31.12 11.82 22 35015 3975 64459720
Nausea 30.55 11.82 597 34440 785203 63678492
Cardio-respiratory arrest 30.28 11.82 8 35029 98385 64365310
PIK3CA-activated mutation 29.46 11.82 11 35026 514 64463181
Tendonitis 29.36 11.82 45 34992 20237 64443458
Progesterone receptor assay positive 29.35 11.82 9 35028 228 64463467
Dental care 29.14 11.82 12 35025 729 64462966
Human epidermal growth factor receptor negative 29.13 11.82 5 35032 5 64463690
Metastatic neoplasm 29.04 11.82 22 35015 4420 64459275
Musculoskeletal chest pain 28.79 11.82 46 34991 21433 64442262
Sequestrectomy 27.57 11.82 12 35025 837 64462858
Metastases to skin 27.06 11.82 14 35023 1438 64462257
Bone sequestrum 26.85 11.82 13 35024 1159 64462536
Systemic lupus erythematosus 26.52 11.82 5 35032 77607 64386088
Second primary malignancy 26.32 11.82 33 35004 12304 64451391
Growth retardation 26.11 11.82 14 35023 1547 64462148
Sepsis 25.82 11.82 54 34983 230287 64233408
Secondary hypogonadism 25.71 11.82 9 35028 349 64463346
Breast pain 25.71 11.82 25 35012 7036 64456659
Metastases to the mediastinum 25.69 11.82 10 35027 524 64463171
Organising pneumonia 25.62 11.82 28 35009 9027 64454668
Fibrous histiocytoma 25.60 11.82 10 35027 529 64463166
Radiation skin injury 25.30 11.82 13 35024 1317 64462378
Acute kidney injury 25.29 11.82 142 34895 449098 64014597
Osteomyelitis 25.25 11.82 50 34987 27537 64436158
Periodontal disease 25.06 11.82 14 35023 1677 64462018
Metastases to soft tissue 24.91 11.82 9 35028 383 64463312
Tooth disorder 24.74 11.82 44 34993 22358 64441337
Pancreatic neoplasm 24.71 11.82 13 35024 1382 64462313
Hair texture abnormal 24.48 11.82 17 35020 2987 64460708
Stomatitis 24.40 11.82 121 34916 109484 64354211
Nail infection 23.91 11.82 14 35023 1833 64461862
Pyrexia 23.75 11.82 192 34845 558452 63905243
Cutaneous vasculitis 23.72 11.82 23 35014 6450 64457245
Glucose tolerance decreased 23.46 11.82 6 35031 76 64463619
Uterine leiomyoma 23.38 11.82 21 35016 5348 64458347
Papilloedema 22.93 11.82 21 35016 5484 64458211
Meningioma 22.71 11.82 18 35019 3864 64459831
Superinfection 22.69 11.82 18 35019 3868 64459827
Mesenteric vein thrombosis 22.68 11.82 12 35025 1290 64462405
Portal hypertension 22.60 11.82 22 35015 6197 64457498
Recall phenomenon 22.57 11.82 11 35026 995 64462700
Rheumatoid arthritis 22.48 11.82 34 35003 164260 64299435
Dry skin 22.48 11.82 70 34967 51091 64412604
Lower limb fracture 22.41 11.82 32 35005 13513 64450182
Pathological fracture 22.33 11.82 26 35011 8979 64454716
Mouth swelling 22.29 11.82 20 35017 5087 64458608
Nail avulsion 21.94 11.82 6 35031 100 64463595
Metastases to retroperitoneum 21.61 11.82 8 35029 365 64463330
Palmar-plantar erythrodysaesthesia syndrome 21.45 11.82 48 34989 28771 64434924
Haemorrhoids 21.37 11.82 43 34994 23958 64439737
Ascites 21.21 11.82 78 34959 61923 64401772
Carcinoembryonic antigen increased 21.14 11.82 13 35024 1860 64461835
Interstitial lung disease 21.12 11.82 107 34930 97625 64366070
Carbohydrate antigen 27.29 increased 21.11 11.82 5 35032 45 64463650
Product substitution issue 20.91 11.82 36 35001 17825 64445870
Tumour marker decreased 20.91 11.82 5 35032 47 64463648
Septic shock 20.90 11.82 16 35021 105421 64358274
Intentional product use issue 20.85 11.82 13 35024 95351 64368344
Borrelia infection 20.29 11.82 6 35031 134 64463561
Chronic inflammatory demyelinating polyradiculoneuropathy 20.27 11.82 10 35027 929 64462766
Bone debridement 20.24 11.82 8 35029 437 64463258
Hepatic lesion 20.05 11.82 20 35017 5804 64457891
Antisynthetase syndrome 20.00 11.82 6 35031 141 64463554
Metastases to peritoneum 19.80 11.82 16 35021 3531 64460164
Paraesthesia 19.78 11.82 133 34904 134389 64329306
Retinal detachment 19.73 11.82 23 35014 7953 64455742
Atypical femur fracture 19.72 11.82 18 35019 4680 64459015
Breast mass 19.71 11.82 19 35018 5291 64458404
Drug hypersensitivity 19.60 11.82 65 34972 237750 64225945
Pustule 19.41 11.82 11 35026 1354 64462341
Vertebral column mass 19.21 11.82 6 35031 162 64463533
Jaw operation 19.16 11.82 9 35028 750 64462945
Cardiac arrest 19.10 11.82 34 35003 154030 64309665
Asthenia 18.91 11.82 332 34705 427712 64035983
Invasive lobular breast carcinoma 18.67 11.82 8 35029 537 64463158
Spondylolisthesis 18.63 11.82 14 35023 2780 64460915
Blood oestrogen increased 18.41 11.82 5 35032 81 64463614
Recurrent cancer 18.33 11.82 13 35024 2360 64461335
Performance enhancing product use 18.24 11.82 5 35032 84 64463611
Autoimmune pancreatitis 18.01 11.82 8 35029 586 64463109
Osteosclerosis 17.94 11.82 15 35022 3471 64460224
Transient acantholytic dermatosis 17.92 11.82 5 35032 90 64463605
Respiratory failure 17.87 11.82 38 34999 161145 64302550
Oroantral fistula 17.68 11.82 7 35030 384 64463311
Dysgeusia 17.64 11.82 61 34976 46986 64416709
Mood swings 17.63 11.82 33 35004 17435 64446260
Pericarditis 17.57 11.82 6 35031 62510 64401185
Excessive eye blinking 17.50 11.82 10 35027 1250 64462445
Neuroectodermal neoplasm 17.48 11.82 3 35034 3 64463692
General physical health deterioration 17.45 11.82 55 34982 204370 64259325
Actinomycosis 17.32 11.82 9 35028 933 64462762
Intraductal proliferative breast lesion 17.12 11.82 12 35025 2139 64461556
Neoplasm recurrence 17.03 11.82 15 35022 3724 64459971
Benign lymph node neoplasm 17.02 11.82 3 35034 4 64463691
Oestradiol decreased 17.02 11.82 3 35034 4 64463691
Hyperkalaemia 16.87 11.82 18 35019 101111 64362584
Henoch-Schonlein purpura 16.85 11.82 12 35025 2194 64461501
Rhabdomyolysis 16.84 11.82 15 35022 91711 64371984
Mastectomy 16.66 11.82 9 35028 1009 64462686
Breast swelling 16.42 11.82 9 35028 1039 64462656
Hypoaesthesia teeth 16.42 11.82 4 35033 41 64463654
Blood pressure fluctuation 16.38 11.82 4 35033 51867 64411828
Febrile neutropenia 16.36 11.82 50 34987 187607 64276088
Retinopathy 16.33 11.82 14 35023 3351 64460344
Pain in extremity 16.33 11.82 243 34794 302842 64160853
Madarosis 16.26 11.82 12 35025 2318 64461377
Pneumonia aspiration 16.13 11.82 6 35031 59265 64404430
Breast haemorrhage 16.11 11.82 5 35032 132 64463563
Vitreous adhesions 16.08 11.82 4 35033 45 64463650
Ischaemic stroke 15.91 11.82 43 34994 28992 64434703
Exposed bone in jaw 15.90 11.82 14 35023 3473 64460222
Blood testosterone increased 15.87 11.82 8 35029 778 64462917
Unresponsive to stimuli 15.69 11.82 4 35033 50389 64413306
Gastrointestinal haemorrhage 15.69 11.82 30 35007 132282 64331413
Varicophlebitis 15.66 11.82 3 35034 8 64463687
Rhabdomyosarcoma 15.63 11.82 5 35032 146 64463549
Autoimmune hepatitis 15.48 11.82 23 35014 10061 64453634
Uveitis 15.39 11.82 26 35011 12682 64451013
Hypersensitivity 15.30 11.82 55 34982 196397 64267298
Vascular purpura 15.27 11.82 12 35025 2544 64461151
Abdominal wall cyst 15.16 11.82 3 35034 10 64463685
Portal vein thrombosis 15.12 11.82 16 35021 4975 64458720
Hair colour changes 15.10 11.82 14 35023 3713 64459982
Breast cancer in situ 15.09 11.82 8 35029 864 64462831
Pleural effusion 15.08 11.82 119 34918 126440 64337255
Metabolic acidosis 15.07 11.82 10 35027 70948 64392747
Joint swelling 15.04 11.82 63 34974 215319 64248376
Cholestasis 14.97 11.82 56 34981 44816 64418879
Lichen sclerosus 14.88 11.82 8 35029 889 64462806
Intermenstrual bleeding 14.77 11.82 16 35021 5109 64458586
Bacteriuria 14.51 11.82 8 35029 934 64462761
Agitation 14.44 11.82 16 35021 88351 64375344
Oral pain 14.35 11.82 40 34997 27453 64436242
Dental caries 14.29 11.82 23 35014 10777 64452918
BRCA2 gene mutation 14.28 11.82 4 35033 73 64463622
Full blood count abnormal 14.28 11.82 42 34995 29715 64433980
Hypercholesterolaemia 14.23 11.82 28 35009 15345 64448350
Squamous cell breast carcinoma 14.19 11.82 3 35034 15 64463680
Atrial enlargement 14.16 11.82 7 35030 653 64463042
Back pain 14.03 11.82 202 34835 249969 64213726
Uterine cancer 13.95 11.82 12 35025 2886 64460809
Postoperative wound complication 13.90 11.82 9 35028 1409 64462286
Confusional state 13.89 11.82 84 34953 261060 64202635
Tooth loss 13.79 11.82 17 35020 6230 64457465
Injection site erythema 13.70 11.82 11 35026 70789 64392906
Visual acuity reduced 13.69 11.82 39 34998 27102 64436593
Sjogren's syndrome 13.65 11.82 7 35030 706 64462989
Subacute cutaneous lupus erythematosus 13.50 11.82 12 35025 3013 64460682
Peripheral sensory neuropathy 13.41 11.82 23 35014 11355 64452340
Dysaesthesia 13.36 11.82 15 35022 4980 64458715
Renal vein thrombosis 13.36 11.82 6 35031 451 64463244
Pelvic mass 13.35 11.82 8 35029 1092 64462603
Alopecia areata 13.28 11.82 9 35028 1519 64462176
Tremor 13.27 11.82 39 34998 148191 64315504
Visual field defect 13.11 11.82 19 35018 8127 64455568
Blood copper increased 13.09 11.82 3 35034 23 64463672
Off label use 13.01 11.82 254 34783 632552 63831143
Metastases to ovary 12.94 11.82 5 35032 257 64463438
Tachycardia 12.93 11.82 40 34997 149539 64314156
Toothache 12.90 11.82 29 35008 17430 64446265
Gingivitis 12.53 11.82 18 35019 7641 64456054
Chronic hepatic failure 12.42 11.82 7 35030 852 64462843
Inner ear disorder 12.41 11.82 6 35031 533 64463162
Menopause 12.38 11.82 9 35028 1699 64461996
Metastases to abdominal wall 12.31 11.82 4 35033 123 64463572
Chronic hepatitis 12.31 11.82 8 35029 1260 64462435
Mucosal ulceration 12.29 11.82 9 35028 1718 64461977
Breast cancer stage IV 12.25 11.82 6 35031 549 64463146
Dyshidrotic eczema 12.18 11.82 6 35031 556 64463139
Cervical polyp 12.16 11.82 4 35033 128 64463567
Multiple organ dysfunction syndrome 12.02 11.82 23 35014 101390 64362305
Hormone receptor positive breast cancer 12 11.82 5 35032 313 64463382
Neoplasm malignant 11.99 11.82 35 35002 24653 64439042
Eosinophilia 11.90 11.82 3 35034 38073 64425622
Respiratory arrest 11.89 11.82 7 35030 52978 64410717

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L02BG03 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ENDOCRINE THERAPY
HORMONE ANTAGONISTS AND RELATED AGENTS
Aromatase inhibitors
FDA MoA N0000175080 Aromatase Inhibitors
FDA EPC N0000175563 Aromatase Inhibitor
CHEBI has role CHEBI:35610 antineoplastic agents
CHEBI has role CHEBI:50790 aromatase inhibitors
MeSH PA D000970 Antineoplastic Agents
MeSH PA D018931 Antineoplastic Agents, Hormonal
MeSH PA D047072 Aromatase Inhibitors
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D004965 Estrogen Antagonists
MeSH PA D006727 Hormone Antagonists
MeSH PA D065088 Steroid Synthesis Inhibitors

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Hormone receptor positive malignant neoplasm of breast indication 417181009
Malignant tumor of ovary off-label use 363443007 DOID:2394
Hypercholesterolemia contraindication 13644009
Pregnancy, function contraindication 289908002
Osteopenia contraindication 312894000
Breastfeeding (mother) contraindication 413712001
Myocardial ischemia contraindication 414795007 DOID:3393




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 3.56 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Aromatase Enzyme INHIBITOR IC50 6.22 WOMBAT-PK CHEMBL

External reference:

IDSource
4020948 VUID
N0000148427 NUI
D00960 KEGG_DRUG
262485 RXNORM
C0290883 UMLSCUI
CHEBI:2704 CHEBI
CHEMBL1399 ChEMBL_ID
DB01217 DRUGBANK_ID
D000077384 MESH_DESCRIPTOR_UI
2187 PUBCHEM_CID
5137 IUPHAR_LIGAND_ID
7274 INN_ID
2Z07MYW1AZ UNII
173198 MMSL
4200 MMSL
5599 MMSL
d03873 MMSL
005094 NDDF
4020948 VANDF
108774000 SNOMEDCT_US
386910003 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Anastrozole HUMAN PRESCRIPTION DRUG LABEL 1 0093-7536 TABLET, FILM COATED 1 mg ORAL ANDA 28 sections
ARIMIDEX HUMAN PRESCRIPTION DRUG LABEL 1 0310-0201 TABLET 1 mg ORAL NDA 28 sections
Anastrozole HUMAN PRESCRIPTION DRUG LABEL 1 0781-5356 TABLET, FILM COATED 1 mg ORAL ANDA 29 sections
Anastrozole HUMAN PRESCRIPTION DRUG LABEL 1 0904-6195 TABLET 1 mg ORAL ANDA 26 sections
Anastrozole Human Prescription Drug Label 1 16571-421 TABLET 1 mg ORAL ANDA 29 sections
Anastrozole HUMAN PRESCRIPTION DRUG LABEL 1 16729-035 TABLET 1 mg ORAL ANDA 26 sections
Anastrozole HUMAN PRESCRIPTION DRUG LABEL 1 21695-990 TABLET 1 mg ORAL ANDA 27 sections
Anastrozole HUMAN PRESCRIPTION DRUG LABEL 1 42254-161 TABLET 1 mg ORAL ANDA 28 sections
Anastrozole HUMAN PRESCRIPTION DRUG LABEL 1 42291-085 TABLET, FILM COATED 1 mg ORAL ANDA 28 sections
ANASTROZOLE HUMAN PRESCRIPTION DRUG LABEL 1 43063-383 TABLET 1 mg ORAL ANDA 31 sections
Anastrozole HUMAN PRESCRIPTION DRUG LABEL 1 45865-909 TABLET 1 mg ORAL ANDA 27 sections
Anastrozole HUMAN PRESCRIPTION DRUG LABEL 1 50090-2453 TABLET 1 mg ORAL ANDA 28 sections
Anastrozole HUMAN PRESCRIPTION DRUG LABEL 1 50090-2453 TABLET 1 mg ORAL ANDA 28 sections
ANASTROZOLE HUMAN PRESCRIPTION DRUG LABEL 1 50090-5002 TABLET 1 mg ORAL ANDA 30 sections
Anastrozole Human Prescription Drug Label 1 50090-5812 TABLET, FILM COATED 1 mg ORAL ANDA 28 sections
ANASTROZOLE HUMAN PRESCRIPTION DRUG LABEL 1 50268-075 TABLET 1 mg ORAL ANDA 31 sections
Anastrozole HUMAN PRESCRIPTION DRUG LABEL 1 51655-638 TABLET 1 mg ORAL ANDA 15 sections
ANASTROZOLE HUMAN PRESCRIPTION DRUG LABEL 1 51991-620 TABLET 1 mg ORAL ANDA 31 sections
ARIMIDEX HUMAN PRESCRIPTION DRUG LABEL 1 54868-5000 TABLET 1 mg ORAL NDA 28 sections
Anastrozole HUMAN PRESCRIPTION DRUG LABEL 1 54868-6130 TABLET 1 mg ORAL ANDA 27 sections
Testozole HUMAN PRESCRIPTION DRUG LABEL 2 57377-060 PELLET, IMPLANTABLE 4 mg SUBCUTANEOUS unapproved drug other 8 sections
Testozole HUMAN PRESCRIPTION DRUG LABEL 2 57377-060 PELLET, IMPLANTABLE 4 mg SUBCUTANEOUS unapproved drug other 8 sections
Anastrozole Human Prescription Drug Label 1 59651-236 TABLET, FILM COATED 1 mg ORAL ANDA 28 sections
Anastrozole HUMAN PRESCRIPTION DRUG LABEL 1 60429-286 TABLET, FILM COATED 1 mg ORAL ANDA 27 sections
Anastrozole HUMAN PRESCRIPTION DRUG LABEL 1 60687-112 TABLET, COATED 1 mg ORAL ANDA 28 sections
Anastrozole HUMAN PRESCRIPTION DRUG LABEL 1 60763-376 TABLET 1 mg ORAL ANDA 27 sections
Anastrozole HUMAN PRESCRIPTION DRUG LABEL 1 60763-388 TABLET 1 mg ORAL Export only 27 sections
Anastrozole HUMAN PRESCRIPTION DRUG LABEL 1 62033-0376 TABLET, COATED 1 mg ORAL Export only 17 sections
Anastrozole HUMAN PRESCRIPTION DRUG LABEL 1 62135-490 TABLET 1 mg ORAL ANDA 30 sections
Anastrozole HUMAN PRESCRIPTION DRUG LABEL 1 62175-710 TABLET, FILM COATED 1 mg ORAL ANDA 28 sections